Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -37K | -33K | -32K | -41K |
| Operating Income | -20M | -42M | -38M | -38M | -30M |
| EBITDA | -23M | -41M | -38M | -38M | -30M |
| Net Income | -31M | -47M | -41M | -39M | -31M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.24
+8.04% today
1Y Change
+12.34%
Window
Jun 26, 2025 → Jun 16, 2026
Coverage: 244 bars · Jun 26, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Galectin Therapeutics Inc. (GALT) is a Healthcare stock with a market cap of $150.00M and listed on NASDAQ. The stock last traded around $4.24 and up 12.3% across the available one-year price window (Jun 26, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +36.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +36.8%, free cash flow +42.8% with operating margin 0.0% and ROIC -174.3%. Stock Foundry combines GALT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GALT
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GALT Max Drawdown
-68.05%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for GALT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$30.5M
+21.3% YoY
Free Cash Flow
-$24.3M
+21.7% YoY
Revenue Growth
+0.0%
EPS Growth
+36.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -37K | -33K | -32K | -41K |
| Operating Income | -20M | -42M | -38M | -38M | -30M |
| EBITDA | -23M | -41M | -38M | -38M | -30M |
| Net Income | -31M | -47M | -41M | -39M | -31M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18M | 15M | 26M | 19M | 40M |
| Total Assets | 20M | 17M | 28M | 21M | 42M |
| Total Liabilities | 146M | 121M | 88M | 53M | 39M |
| Shareholder Equity | -126M | -103M | -60M | -32M | 3M |
| Total Debt | 134M | 106M | 72M | 40M | 29M |
| Net Debt | 116M | 91M | 46M | 21M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24M
+21.7% YoY
Capital Expenditures
0
Free Cash Flow
24M
+21.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
25.6%
Debt / Equity
-1.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.